Yosafe Wakwaya, MD
Pulmonary Disease · Dallas, TXNPI 1205275336
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,300 of the $14,020 with a category attached, or 73.5%. Boehringer Ingelheim International GmbH accounts for 73.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $11,035 and has fallen 85.8% since, to $1,564 in 2025.
Across 164 payments — averaging $85.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$10K
- GSK$790
- AstraZeneca$608
- Insmed, Inc.$376
- Regeneron Healthcare Solutions, Inc.$354
- Sanofi$265
- plus $1K from 17 others
Across 142 payments — averaging $2989.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$425K
What the payments were for
- Consulting fees$10,30073%
- Food & beverage$3,59226%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 1 | $10,300 |
| GSK | 43 | $790 |
| AstraZeneca | 34 | $608 |
| Insmed, Inc. | 17 | $376 |
| Regeneron Healthcare Solutions, Inc. | 10 | $354 |
| Sanofi | 9 | $265 |
| Merck | 9 | $206 |
| Boehringer Ingelheim | 8 | $193 |
| Amgen | 7 | $136 |
| United Therapeutics Corporation | 1 | $128 |
| Vifor Pharma, Inc. | 5 | $127 |
| Grifols USA, LLC | 5 | $122 |
| Penumbra, Inc. | 1 | $113 |
| Itamar Medical Inc | 2 | $57 |
| Verona Pharma, Inc. | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Baxter Healthcare | 2 | $31 |
| Shionogi Inc | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Alafair Biosciences, Inc. | 1 | $25 |
| Electromed, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$10,300
- TYVASO$128
- Indigo System$113
How this compares
$14,020 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 132 | $1,755,677 |
| Tyvaso DpiTreprostinil | 15 | $351,270 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $106,255 |
| Pirfenidone | 47 | $84,948 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $31,535 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,775 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $17,694 |
| Mycophenolate Mofetil | 73 | $14,528 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,756 |
| Spiriva HandihalerTiotropium Bromide | 11 | $7,475 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $4,370 |
| Mycophenolic AcidMycophenolate Sodium | 26 | $4,203 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,244 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,412 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $193 | $1,755,677132 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $790 | $158,728231 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $608 | $30,53148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.